 |
|
|
|
|
|
|
|
 |
|
||||||
 |
 |
 |
 |
 |
 |
 |
|
Analyst Conference Summaries
Sage Therapeutics
SAGE
conference date: May 2, 2023 @ 5:00 AM Pacific Time
Sage Therapeutics' Deal With Biogen Should Revive It [December 11, 2020 at Seeking Alpha]
| 2023 | |||
| Sage Therapeutics Q1 2023 |
|||
| May 2, 2023 | |||
| 2022 | |||
| Sage Therapeutics Q1 2022 |
Sage Therapeutics Q2 2022 |
Sage Therapeutics Q3 2022 |
Sage Therapeutics Q4 2022 |
| May 3, 2022 | Aug. 2, 2022 | Nov. 8, 2022 | Feb. 16, 2023 |
| 2021 | |||
| Sage Therapeutics Q1 2021 |
Sage Therapeutics Q2 2021 |
Sage Therapeutics Q3 2021 |
Sage Therapeutics Q4 2021 |
| May 4, 2021 | Aug. 3, 2021 | Nov. 2, 2021 | Feb. 24, 2022 |
| 2020 | |||
| Sage Therapeutics Q3 2020 |
Sage Therapeutics Q4 2020 |
||
| Nov. 5, 2020 | Feb. 24, 2021 | ||
Sage Therapeutics (SAGE) is a commercial stage biotechnology company specializing in therapies for brain disorders.
More Analyst Conference Pages:
| AGEN |
| AGIO |
| ALNY |
| AMAT |
| AMGN |
| BIIB |
| BMY |
| CDTX |
| CLDX |
| FATE |
| GILD |
| GLYC |
| ILMN |
| INO |
| IONS |
| MCHP |
| MRNA |
| PLX |
| REGN |
| RNA |
| SANA |
| SGEN |
| SYRS |
| VRTX |
| VSTM |
| WBA |
Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.
Copyright 2023 William P. Meyers